Dmitrii V. Kalinin

Dr. Dmitrii V. Kalinin

Institute of Pharmaceutical and Medicinal Chemistry; University of Münster, Munster, Germany
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MMMartin Marek
Martin Marek
TSTajith Baba Shaik
Tajith Baba Shaik
THTino Heimburg
Tino Heimburg
ACAlokta Chakrabarti
Alokta Chakrabarti
JLJulien Lancelot
Julien Lancelot
CRChristophe Romier
Christophe Romier

12 July 2017 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
DKDmitrii V. Kalinin
Dmitrii V. Kalinin
Ralph HollRalph Holl
Ralph Holl
Introduction: The Zn2+-dependent deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising target for the development of antibiotics selectively combating Gram-negative pathogens. Researchers from industry and academia have synthesized structurally diverse LpxC inhibitors, exhibiting different LpxC inhibitory and antibacterial activities. Areas covered: A brief introduction into the structure and function of LpxC, showing its suitability as antibacterial target, along with the structures of several reported LpxC inhibitors, is given. The article reviews patents (reported between 2010 and 2016) and related research publications on novel small-molecule LpxC inhibitors. Emphasis is placed on structure-activity relationships within the reported series of LpxC inhibitors. Expert opinion: The performed analysis of patents revealed that the current search for novel LpxC inhibitors is focused on small molecules, sharing common structural features like a Zn2+-chelating group as well as a highly lipophilic side-chain. However, despite the promising preclinical data of many of the reported compounds, besides the recently withdrawn clinical candidate ACHN-975, no other LpxC inhibitor has entered clinical trials. The lack of clinical candidates might be related with undesired effects caused by the common structural elements of the LpxC inhibitors.

27 July 2021 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
DKDmitrii V. Kalinin
Dmitrii V. Kalinin
Introduction: Blood coagulation factor XII (FXII) is an emerging and potentially safe drug target, which dysregulation is associated with thrombosis, hereditary angioedema, and (neuro)inflammation. At the same time, FXII-deficiency is practically asymptomatic. Industrial and academic institutions have developed a number of potential therapeutic agents targeting either FXII zymogen or its active form FXIIa for the treatment of thrombotic and inflammatory conditions associated with the activity of this enzyme. Areas covered: A short overview of the FXII(a) structure and function, underlining its suitability as a drug target, is given. The article reviews patents reported over the last three decades on FXII(a)-targeting therapeutic agents. These agents include small molecules, proteins, peptides, oligonucleotides, siRNAs, and monoclonal antibodies. Expert opinion: The performed analysis of patents revealed that many FXII(a) inhibitors are in the early preclinical stage, while several already showed efficacy in vivo animal models of thrombosis, sepsis, hereditary angioedema, and multiple sclerosis. Two anti-FXIIa agents namely tick protein Ir-CPI and monoclonal antibody CSL312 are currently in human clinical trials. The results of these trials and further studies of FXII(a) pathophysiological functions will encourage the development of new FXII(a) inhibitors.

30 June 2016 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
DKDmitrii V. Kalinin
Dmitrii V. Kalinin
Ralph HollRalph Holl
Ralph Holl
The bacterial enzyme UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase (LpxC), catalyzing the first committed step of lipid A biosynthesis, represents a promising target in the development of novel antibiotics against Gram-negative bacteria. Structure, catalytic reaction mechanism and regulation of the Zn2+-dependent metalloamidase have been intensively investigated. The enzyme is required for growth and viability of Gram-negative bacteria, displays no sequence homology with any mammalian protein, but is highly conserved in Gram-negative bacteria, thus permitting the development of Gram-negative selective antibacterial agents with limited off-target effects. Several smallmolecule LpxC inhibitors have been developed, like the substrate analog TU-514 (12a), the aryloxazoline L-161,240 (13w), the sulfonamide BB-78485 (23a), the N-aroyl-L-threonine derivative CHIR-090 (24a), the sulfone-containing pyridone LpxC-3 (43e), and the uridine-based inhibitor 1-68A (47a), displaying diverse inhibitory and antibacterial activities. Most of these compounds share a Zn2+-binding hydroxamate moiety attached to a structural element addressing the hydrophobic tunnel or the UDP binding site. The butadiynyl derivative ACHN-975 (28) is the first LpxC inhibitor entering clinical trials.

13 December 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GTGiovanni Tangherlini
Giovanni Tangherlini
DKDmitrii V. Kalinin
Dmitrii V. Kalinin
DSDirk Schepmann
Dirk Schepmann
TCTao Che
Tao Che
NMNadine Mykicki
Nadine Mykicki
BWBernhard Wünsch
Bernhard Wünsch

22 October 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MKMarvin Korff
Marvin Korff
LILukas Imberg
Lukas Imberg
JWJonas M. Will
Jonas M. Will
NBNico Bückreiß
Nico Bückreiß
SKSvetlana A. Kalinina
Svetlana A. Kalinina
DKDmitrii V. Kalinin
Dmitrii V. Kalinin